Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 454.25
(-3.03%)
USD 454.25
(-3.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -9.56 Billion USD | 3.81% |
| 2022 | -9.94 Billion USD | -59.39% |
| 2021 | -6.23 Billion USD | -15.38% |
| 2020 | -5.4 Billion USD | -113.54% |
| 2019 | -2.53 Billion USD | -21.55% |
| 2018 | -2.08 Billion USD | -89.1% |
| 2017 | -1.1 Billion USD | -218.63% |
| 2016 | -345.69 Million USD | -426.6% |
| 2015 | 105.84 Million USD | -47.09% |
| 2014 | 200.03 Million USD | 255.84% |
| 2013 | -128.36 Million USD | -170.06% |
| 2012 | 183.22 Million USD | 343.26% |
| 2011 | -75.32 Million USD | -125.64% |
| 2010 | 293.79 Million USD | 200.33% |
| 2009 | -292.82 Million USD | -188.17% |
| 2008 | -101.61 Million USD | 69.73% |
| 2007 | -335.66 Million USD | -275.4% |
| 2006 | -89.41 Million USD | -187.62% |
| 2005 | 102.05 Million USD | -63.55% |
| 2004 | 279.99 Million USD | 13.25% |
| 2003 | 247.22 Million USD | 12.36% |
| 2002 | 220.04 Million USD | 58.99% |
| 2001 | 138.4 Million USD | 401.45% |
| 2000 | 27.6 Million USD | 213.11% |
| 1999 | -24.4 Million USD | -69.44% |
| 1998 | -14.4 Million USD | 77.18% |
| 1997 | -63.1 Million USD | -139.02% |
| 1996 | -26.4 Million USD | -23.36% |
| 1995 | -21.4 Million USD | 67.18% |
| 1994 | -65.2 Million USD | -188.5% |
| 1993 | -22.6 Million USD | -247.69% |
| 1992 | -6.5 Million USD | 73.25% |
| 1991 | -24.3 Million USD | -1925.0% |
| 1990 | -1.2 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -8.43 Billion USD | 11.79% |
| 2024 Q2 | -3.64 Billion USD | 56.78% |
| 2024 Q3 | -3.53 Billion USD | 3.03% |
| 2023 Q1 | -8.5 Billion USD | 14.51% |
| 2023 Q3 | -10.36 Billion USD | -10.47% |
| 2023 FY | -9.56 Billion USD | 3.81% |
| 2023 Q2 | -9.38 Billion USD | -10.39% |
| 2023 Q4 | -9.56 Billion USD | 7.73% |
| 2022 FY | -9.94 Billion USD | -59.39% |
| 2022 Q2 | -8.17 Billion USD | -15.8% |
| 2022 Q3 | -8.68 Billion USD | -6.35% |
| 2022 Q4 | -9.94 Billion USD | -14.43% |
| 2022 Q1 | -7.05 Billion USD | -13.11% |
| 2021 Q2 | -5.49 Billion USD | 4.14% |
| 2021 FY | -6.23 Billion USD | -15.38% |
| 2021 Q1 | -5.73 Billion USD | -6.01% |
| 2021 Q3 | -5.71 Billion USD | -4.06% |
| 2021 Q4 | -6.23 Billion USD | -9.12% |
| 2020 Q4 | -5.4 Billion USD | -13.34% |
| 2020 Q2 | -4.26 Billion USD | -41.33% |
| 2020 Q3 | -4.77 Billion USD | -11.75% |
| 2020 FY | -5.4 Billion USD | -113.54% |
| 2020 Q1 | -3.02 Billion USD | -19.3% |
| 2019 Q1 | -2.29 Billion USD | -10.31% |
| 2019 FY | -2.53 Billion USD | -21.55% |
| 2019 Q4 | -2.53 Billion USD | 10.19% |
| 2019 Q3 | -2.81 Billion USD | -4.18% |
| 2019 Q2 | -2.7 Billion USD | -17.77% |
| 2018 Q1 | -1.42 Billion USD | -29.68% |
| 2018 Q4 | -2.08 Billion USD | -8.91% |
| 2018 Q2 | -1.57 Billion USD | -10.28% |
| 2018 Q3 | -1.91 Billion USD | -21.41% |
| 2018 FY | -2.08 Billion USD | -89.1% |
| 2017 Q2 | -697.58 Million USD | -38.3% |
| 2017 Q4 | -1.1 Billion USD | -31.53% |
| 2017 FY | -1.1 Billion USD | -218.63% |
| 2017 Q1 | -504.39 Million USD | -45.91% |
| 2017 Q3 | -837.42 Million USD | -20.05% |
| 2016 FY | -345.69 Million USD | -426.6% |
| 2016 Q3 | 96.05 Million USD | -55.37% |
| 2016 Q4 | -345.69 Million USD | -459.91% |
| 2016 Q2 | 215.22 Million USD | -2.48% |
| 2016 Q1 | 220.69 Million USD | 108.51% |
| 2015 Q3 | 64.73 Million USD | 240.49% |
| 2015 Q1 | 169.02 Million USD | -15.5% |
| 2015 Q2 | -46.07 Million USD | -127.26% |
| 2015 FY | 105.84 Million USD | -47.09% |
| 2015 Q4 | 105.84 Million USD | 63.51% |
| 2014 Q1 | 49.31 Million USD | 138.42% |
| 2014 Q3 | 49.34 Million USD | -6.38% |
| 2014 FY | 200.03 Million USD | 255.84% |
| 2014 Q4 | 200.03 Million USD | 305.36% |
| 2014 Q2 | 52.71 Million USD | 6.88% |
| 2013 Q4 | -128.36 Million USD | 32.66% |
| 2013 Q3 | -190.61 Million USD | -10.73% |
| 2013 Q2 | -172.14 Million USD | -150.97% |
| 2013 Q1 | 337.72 Million USD | 84.32% |
| 2013 FY | -128.36 Million USD | -170.06% |
| 2012 Q3 | -36.88 Million USD | 31.77% |
| 2012 FY | 183.22 Million USD | 343.26% |
| 2012 Q1 | 132.07 Million USD | 275.35% |
| 2012 Q4 | 183.22 Million USD | 596.73% |
| 2012 Q2 | -54.06 Million USD | -140.93% |
| 2011 Q2 | -58.19 Million USD | -25.05% |
| 2011 FY | -75.32 Million USD | -125.64% |
| 2011 Q4 | -75.32 Million USD | 47.16% |
| 2011 Q3 | -142.54 Million USD | -144.94% |
| 2011 Q1 | -46.53 Million USD | -115.84% |
| 2010 Q1 | -271.23 Million USD | 7.37% |
| 2010 FY | 293.79 Million USD | 200.33% |
| 2010 Q4 | 293.79 Million USD | 272.92% |
| 2010 Q3 | -169.9 Million USD | 32.36% |
| 2010 Q2 | -251.2 Million USD | 7.38% |
| 2009 FY | -292.82 Million USD | -188.17% |
| 2009 Q1 | -314.69 Million USD | -209.7% |
| 2009 Q2 | -264.94 Million USD | 15.81% |
| 2009 Q3 | -415.13 Million USD | -56.68% |
| 2009 Q4 | -292.82 Million USD | 29.46% |
| 2008 Q1 | -203.19 Million USD | 39.46% |
| 2008 Q2 | -262.13 Million USD | -29.0% |
| 2008 Q3 | -255.37 Million USD | 2.58% |
| 2008 Q4 | -101.61 Million USD | 60.21% |
| 2008 FY | -101.61 Million USD | 69.73% |
| 2007 Q1 | -289.1 Million USD | -223.32% |
| 2007 Q2 | -106.61 Million USD | 63.12% |
| 2007 FY | -335.66 Million USD | -275.4% |
| 2007 Q4 | -335.66 Million USD | -43.46% |
| 2007 Q3 | -233.98 Million USD | -119.46% |
| 2006 Q1 | 98.27 Million USD | -3.71% |
| 2006 Q4 | -89.41 Million USD | 76.57% |
| 2006 Q2 | 138.66 Million USD | 41.1% |
| 2006 Q3 | -381.68 Million USD | -375.26% |
| 2006 FY | -89.41 Million USD | -187.62% |
| 2005 Q3 | 192.92 Million USD | 37.51% |
| 2005 Q4 | 102.05 Million USD | -47.1% |
| 2005 Q1 | 297.62 Million USD | 6.3% |
| 2005 FY | 102.05 Million USD | -63.55% |
| 2005 Q2 | 140.3 Million USD | -52.86% |
| 2004 Q4 | 279.99 Million USD | -0.94% |
| 2004 Q1 | 262.02 Million USD | 5.99% |
| 2004 Q2 | 258.92 Million USD | -1.19% |
| 2004 Q3 | 282.65 Million USD | 9.16% |
| 2004 FY | 279.99 Million USD | 13.25% |
| 2003 Q1 | 149.12 Million USD | -32.23% |
| 2003 FY | 247.22 Million USD | 12.36% |
| 2003 Q3 | 267.88 Million USD | 29.18% |
| 2003 Q4 | 247.22 Million USD | -7.71% |
| 2003 Q2 | 207.36 Million USD | 39.06% |
| 2002 Q3 | 220.68 Million USD | 10.35% |
| 2002 Q4 | 220.04 Million USD | -0.29% |
| 2002 Q2 | 199.98 Million USD | 33.29% |
| 2002 Q1 | 150.03 Million USD | 8.4% |
| 2002 FY | 220.04 Million USD | 58.99% |
| 2001 Q2 | 180.12 Million USD | 42.4% |
| 2001 Q3 | 162.79 Million USD | -9.62% |
| 2001 FY | 138.4 Million USD | 401.45% |
| 2001 Q4 | 138.4 Million USD | -14.99% |
| 2001 Q1 | 126.49 Million USD | 358.3% |
| 2000 Q4 | 27.6 Million USD | -31.84% |
| 2000 Q3 | 40.49 Million USD | 1797.78% |
| 2000 Q2 | -2.38 Million USD | 76.9% |
| 2000 Q1 | -10.32 Million USD | 57.69% |
| 2000 FY | 27.6 Million USD | 213.11% |
| 1999 Q1 | -10.7 Million USD | 25.69% |
| 1999 Q2 | -2.8 Million USD | 73.83% |
| 1999 Q3 | -14.6 Million USD | -421.43% |
| 1999 Q4 | -24.4 Million USD | -67.12% |
| 1999 FY | -24.4 Million USD | -69.44% |
| 1998 Q2 | -26.7 Million USD | 46.28% |
| 1998 Q1 | -49.7 Million USD | 21.24% |
| 1998 Q3 | -39.3 Million USD | -47.19% |
| 1998 Q4 | -14.4 Million USD | 63.36% |
| 1998 FY | -14.4 Million USD | 77.18% |
| 1997 Q4 | -63.1 Million USD | 62.66% |
| 1997 Q2 | -180.4 Million USD | -134.9% |
| 1997 Q1 | -76.8 Million USD | -190.91% |
| 1997 FY | -63.1 Million USD | -139.02% |
| 1997 Q3 | -169 Million USD | 6.32% |
| 1996 Q1 | -13.7 Million USD | 35.98% |
| 1996 FY | -26.4 Million USD | -23.36% |
| 1996 Q3 | -32.2 Million USD | -1241.67% |
| 1996 Q4 | -26.4 Million USD | 18.01% |
| 1996 Q2 | -2.4 Million USD | 82.48% |
| 1995 Q2 | -37.2 Million USD | 16.96% |
| 1995 Q3 | -32.6 Million USD | 12.37% |
| 1995 Q4 | -21.4 Million USD | 34.36% |
| 1995 FY | -21.4 Million USD | 67.18% |
| 1995 Q1 | -44.8 Million USD | 31.29% |
| 1994 FY | -65.2 Million USD | -188.5% |
| 1994 Q2 | -15.3 Million USD | 68.65% |
| 1994 Q3 | -42.2 Million USD | -175.82% |
| 1994 Q1 | -48.8 Million USD | -115.93% |
| 1994 Q4 | -65.2 Million USD | -54.5% |
| 1993 Q4 | -22.6 Million USD | -148.35% |
| 1993 Q1 | -9.7 Million USD | -49.23% |
| 1993 Q2 | -600 Thousand USD | 93.81% |
| 1993 FY | -22.6 Million USD | -247.69% |
| 1993 Q3 | -9.1 Million USD | -1416.67% |
| 1992 Q2 | -11.9 Million USD | 43.87% |
| 1992 FY | -6.5 Million USD | 73.25% |
| 1992 Q1 | -21.2 Million USD | 12.76% |
| 1992 Q3 | -17.7 Million USD | -48.74% |
| 1992 Q4 | -6.5 Million USD | 63.28% |
| 1991 FY | -24.3 Million USD | -1925.0% |
| 1991 Q2 | 1.2 Million USD | 0.0% |
| 1991 Q3 | -3.9 Million USD | -425.0% |
| 1991 Q4 | -24.3 Million USD | -523.08% |
| 1990 FY | -1.2 Million USD | 0.0% |
| 1990 Q4 | -1.2 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | -10878.351% |
| Dynavax Technologies Corporation | 106.63 Million USD | 9068.819% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -28425.964% |
| Perrigo Company plc | 3.32 Billion USD | 387.887% |
| Illumina, Inc. | 1.21 Billion USD | 887.801% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 135.633% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | -8297.636% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 216.137% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 174.398% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 6692.338% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -35191.144% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 133172.214% |
| Waters Corporation | 1.96 Billion USD | 587.845% |
| Biogen Inc. | 6.28 Billion USD | 252.09% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -134602.817% |
| Evolus, Inc. | 63.7 Million USD | 15112.086% |
| Adicet Bio, Inc. | -142 Million USD | -6634.761% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -105976.974% |
| bluebird bio, Inc. | 108.57 Million USD | 8908.89% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 2185.006% |
| FibroGen, Inc. | 56.76 Million USD | 16947.64% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 935.275% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 137353.095% |
| Homology Medicines, Inc. | 18.43 Million USD | 51973.407% |
| Geron Corporation | 14.76 Million USD | 64891.681% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 703.276% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 4928.667% |
| Myriad Genetics, Inc. | 88.1 Million USD | 10955.732% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -17527.359% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | -8485.034% |
| Zoetis Inc. | 4.76 Billion USD | 300.838% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -94864.75% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 555.866% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 2625.135% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -65532.034% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 1007.156% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 30094.982% |
| Verastem, Inc. | -37.27 Million USD | -25555.615% |
| Nektar Therapeutics | 210.24 Million USD | 4649.039% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | -4686.234% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -25886.034% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 1087.621% |
| OPKO Health, Inc. | 230.68 Million USD | 4245.906% |
| Exelixis, Inc. | -73.05 Million USD | -12992.266% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 5494.191% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | -6963.442% |
| Anavex Life Sciences Corp. | -151.02 Million USD | -6232.702% |
| uniQure N.V. | -102.95 Million USD | -9189.759% |
| Imunon, Inc. | -4.69 Million USD | -203418.714% |
| Blueprint Medicines Corporation | 702.83 Million USD | 1460.758% |
| Insmed Incorporated | 721.62 Million USD | 1425.337% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 792.596% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -30536.832% |
| TG Therapeutics, Inc. | 17.86 Million USD | 53643.276% |
| Incyte Corporation | -3.17 Billion USD | -201.217% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 1348.877% |